Research Online
暂无分享,去创建一个
K. Blennow | D. Ames | Qiao-Xin Li | V. Villemagne | P. Bourgeat | Veer Bala Gupta | Christopher Fowler | M. Best | T. Schlub | M. Ballinger | I. Juraskova | M. Young | A. Newson | J. Savard | Katherine Tucker | Richard Vines | N. Bartley | C. Napier | Kunal Dhiman | Kate Vines | Judy Kirk | Colin L. Masters | Henrik Zetterberg | Christopher C. Rowe | Chris Jacobs | Phyllis N. Butow | Fabiola Müller | Barbara Biesecker | Bettina Meiser | David M. Thomas | David Goldstein | Nicci Bartley MEval | Richard Vines | Ralph N. Martins | Steven J. Collins | AProf.VeerGupta | D. Ames | R. Martins | C. Rowe | Steven J. Collins | C. L. Masters | AProf.VeerGupta
[1] K. Blennow,et al. Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study , 2022, Biomedicines.
[2] K. Blennow,et al. Relationship between cerebrospinal fluid neurodegeneration biomarkers and temporal brain atrophy in cognitively healthy older adults , 2022, Neurobiology of Aging.
[3] F. Jessen,et al. Interrelations of Alzheimer´s disease candidate biomarkers neurogranin, fatty acid‐binding protein 3 and ferritin to neurodegeneration and neuroinflammation , 2020, Journal of neurochemistry.
[4] A. Fonteh,et al. Involvement of Lipids in Alzheimer’s Disease Pathology and Potential Therapies , 2020, Frontiers in Physiology.
[5] K. Blennow,et al. Interleukin 10 and Heart Fatty Acid-Binding Protein as Early Outcome Predictors in Patients With Traumatic Brain Injury , 2020, Frontiers in Neurology.
[6] K. Blennow,et al. Biomarker profiling beyond amyloid and tau: cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults , 2020, Neurobiology of Aging.
[7] Philip S. Insel,et al. Determining clinically meaningful decline in preclinical Alzheimer disease , 2019, Neurology.
[8] K. Blennow,et al. Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer’s disease pathogenesis , 2019, Cellular and Molecular Life Sciences.
[9] Kevin S. Hanson,et al. Effect of age, ethnicity, sex, cognitive status and APOE genotype on amyloid load and the threshold for amyloid positivity , 2019, NeuroImage: Clinical.
[10] Kathryn Goozee,et al. A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer’s disease , 2019, Science Advances.
[11] L. Parnetti,et al. Role of FABP3 as biomarker in Alzheimer's disease and synucleinopathies , 2018, Future Neurology.
[12] Yen-Wen Wu,et al. The prognostic significance of heart-type fatty acid binding protein in patients with stable coronary heart disease , 2018, Scientific Reports.
[13] Joanne S. Robertson,et al. The effect of preclinical Alzheimer's disease on age-related changes in intelligence in cognitively normal older adults , 2018, Intelligence.
[14] Yi Su,et al. Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE &egr;4 genotype , 2018, Brain : a journal of neurology.
[15] C. Jack,et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.
[16] P. Calabresi,et al. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia , 2017, Alzheimer's Research & Therapy.
[17] C. Rowe,et al. Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort , 2017, Alzheimer's & dementia.
[18] K. Schaller,et al. H-FABP: A new biomarker to differentiate between CT-positive and CT-negative patients with mild traumatic brain injury , 2017, PloS one.
[19] R. Martins,et al. Retinal vascular and structural changes are associated with amyloid burden in the elderly: ophthalmic biomarkers of preclinical Alzheimer’s disease , 2017, Alzheimer's Research & Therapy.
[20] K. Blennow,et al. Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration , 2017, Translational Psychiatry.
[21] Keith A. Johnson,et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers , 2016, Neurology.
[22] C. Jack,et al. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria , 2016, Alzheimer's & Dementia.
[23] K. Blennow,et al. Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years. , 2015, Journal of Alzheimer's disease : JAD.
[24] C. Rowe,et al. Comparison of MR-less PiB SUVR quantification methods , 2015, Neurobiology of Aging.
[25] Nick C Fox,et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.
[26] I. Kubota,et al. Association of Heart-Type Fatty Acid-Binding Protein with Cardiovascular Risk Factors and All-Cause Mortality in the General Population: The Takahata Study , 2014, PloS one.
[27] Pierrick Bourgeat,et al. En Attendant Centiloid , 2014 .
[28] David T. Jones,et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity , 2013, Neurology.
[29] O. Andreassen,et al. Heart fatty acid binding protein and Aβ-associated Alzheimer’s neurodegeneration , 2013, Molecular Neurodegeneration.
[30] R. Perneczky,et al. Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer’s disease , 2013, European Archives of Psychiatry and Clinical Neuroscience.
[31] Leslie M. Shaw,et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative , 2012, Alzheimer's & Dementia.
[32] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[33] P. Calabresi,et al. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. , 2011, Journal of Alzheimer's Disease.
[34] E. Salmon,et al. 18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.
[35] C. Rowe,et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.
[36] C. Rowe,et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease , 2009, International Psychogeriatrics.
[37] K. Blennow,et al. Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer's disease and vascular dementia. , 2013, Journal of Alzheimer's disease : JAD.
[38] R. Coleman,et al. Use of Florbetapir-PET for Imaging-Amyloid Pathology , 2011 .